The PROSPER Trial: Chemotherapy-Related Endpoints in Patients with nmCRPC - Neal Shore
Video Player is loading.
August 14, 2018
(Length of Presentation: 9 min)
Neal Shore, MD, FACS shares his 2018 AUA presentation on the groundbreaking PROSPER trial: chemotherapy-related endpoints in patients with nonmetastatic castration-resistant prostate cancer treated with enzalutamide. Meeting an unmet need in this Index 1 patient population with a goal of delaying time to metastasis has the potential to delay cancer-related morbidity and antineoplastic therapies and potentially prolonging overal survival.
Biography:
Neal Shore, MD, FACS
Neal Shore, MD, FACS shares his 2018 AUA presentation on the groundbreaking PROSPER trial: chemotherapy-related endpoints in patients with nonmetastatic castration-resistant prostate cancer treated with enzalutamide. Meeting an unmet need in this Index 1 patient population with a goal of delaying time to metastasis has the potential to delay cancer-related morbidity and antineoplastic therapies and potentially prolonging overal survival.
Biography:
Neal Shore, MD, FACS
Related Content:
Watch: Changing the Standard of Care in the M0 CRPC Patient: PROSPER - A Conversation with Cora Sternberg
Watch: Meeting an Unmet Need in the Non-Metastatic Castration-Resistant Prostate Cancer Patient Population - Maha Hussain
First Presentation - PROSPER: Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)
Watch: Changing the Standard of Care in the M0 CRPC Patient: PROSPER - A Conversation with Cora Sternberg
Watch: Meeting an Unmet Need in the Non-Metastatic Castration-Resistant Prostate Cancer Patient Population - Maha Hussain
First Presentation - PROSPER: Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)